23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually. “We are taking these difficult but […]
© 2024 TechCrunch. All rights reserved. For personal use only.
